793 related articles for article (PubMed ID: 28274850)
41. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
[TBL] [Abstract][Full Text] [Related]
42. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
[TBL] [Abstract][Full Text] [Related]
43. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
Mohamed MS; Hanafy AS; Bassiony MAA; Hussein S
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1368-1372. PubMed ID: 28953002
[TBL] [Abstract][Full Text] [Related]
44. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
[TBL] [Abstract][Full Text] [Related]
45. Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin).
Wahid B; Shami K; Joiya SA; Özuyar SEG; Idrees M
J Med Virol; 2020 Dec; 92(12):3868-3870. PubMed ID: 32419178
[TBL] [Abstract][Full Text] [Related]
46. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
[TBL] [Abstract][Full Text] [Related]
47. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.
Landau DA; Scerra S; Sene D; Resche-Rigon M; Saadoun D; Cacoub P
J Rheumatol; 2010 Mar; 37(3):615-21. PubMed ID: 20110523
[TBL] [Abstract][Full Text] [Related]
48. Birmingham vasculitis activity score, disease extent index and complement factor C3c reflect disease activity best in hepatitis C virus-associated cryoglobulinemic vasculitis.
Lamprecht P; Moosig F; Gause A; Herlyn K; Gross WL
Clin Exp Rheumatol; 2000; 18(3):319-25. PubMed ID: 10895368
[TBL] [Abstract][Full Text] [Related]
49. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Yu ML
J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
[TBL] [Abstract][Full Text] [Related]
50. Sofosbuvir and Daclatsvir in Treatment of Hepatitis C Virus-related Membranoproliferative Glomerulonephritis With Cryoglobulinemia in a Patient With Hepatitis C Genotype 4.
Elmowafy AY; El Maghrabi HM; Zahab MA; Elwasif SM; Bakr MA
Iran J Kidney Dis; 2018 Nov; 12(6):382-384. PubMed ID: 30595569
[TBL] [Abstract][Full Text] [Related]
51. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.
Saadoun D; Resche-Rigon M; Thibault V; Piette JC; Cacoub P
Arthritis Rheum; 2006 Nov; 54(11):3696-706. PubMed ID: 17075881
[TBL] [Abstract][Full Text] [Related]
52. Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
Naggie S; Marks KM; Hughes M; Fierer DS; Macbrayne C; Kim A; Hollabaugh K; Roa J; Symonds B; Brainard DM; McHutchison JG; Peters MG; Kiser JJ; Chung R;
Clin Infect Dis; 2017 Apr; 64(8):1035-1042. PubMed ID: 28329053
[TBL] [Abstract][Full Text] [Related]
53. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.
Deterding K; Höner Zu Siederdissen C; Port K; Solbach P; Sollik L; Kirschner J; Mix C; Cornberg J; Worzala D; Mix H; Manns MP; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2015 Oct; 42(7):889-901. PubMed ID: 26250762
[TBL] [Abstract][Full Text] [Related]
54. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
Pearlman BL; Ehleben C; Perrys M
Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ
Clin Infect Dis; 2016 Dec; 63(11):1405-1411. PubMed ID: 27553375
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ
Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241
[TBL] [Abstract][Full Text] [Related]
57. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Beinhardt S; Al Zoairy R; Ferenci P; Kozbial K; Freissmuth C; Stern R; Stättermayer AF; Stauber R; Strasser M; Zoller H; Watschinger B; Schmidt A; Trauner M; Hofer H; Maieron A
Transpl Int; 2016 Sep; 29(9):999-1007. PubMed ID: 27203857
[TBL] [Abstract][Full Text] [Related]
58. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
Brown RS; O'Leary JG; Reddy KR; Kuo A; Morelli GJ; Burton JR; Stravitz RT; Durand C; Di Bisceglie AM; Kwo P; Frenette CT; Stewart TG; Nelson DR; Fried MW; Terrault NA;
Liver Transpl; 2016 Jan; 22(1):24-33. PubMed ID: 26519873
[TBL] [Abstract][Full Text] [Related]
59. Evolution of Cryoglobulinemia in Direct-Acting Antiviral-Treated Asian Hepatitis C Patients With Sustained Virological Responses: A 4-Year Prospective Cohort Study.
Chang ML; Cheng JS; Chuang YH; Pao LH; Wu TS; Chen SC; Chang MY; Chien RN
Front Immunol; 2022; 13():823160. PubMed ID: 35371039
[TBL] [Abstract][Full Text] [Related]
60. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
Punzalan CS; Barry C; Zacharias I; Rodrigues J; Mehta S; Bozorgzadeh A; Barnard GF
Clin Transplant; 2015 Dec; 29(12):1105-11. PubMed ID: 26358816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
